dm+d

Unassigned

New Medicines

Alzheimer's disease in patients who are positive for E4 allele of apoliproprotein E gene

Information

New molecular entity
Not Known
Alzheon

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Amyloid beta-protein inhibitor
Around 600,000-650,000 people have dementia in England and Wales, with 35-60% being of the Alzheimer type (= between 210,000 and 390,000 people). AD progression is dependent on age, with a time from diagnosis to death of about 5−20 years, and a median survival from onset of dementia to death of 7.1 years [NICE TA217, Mar 11]. About 50 - 60 % of the Alzheimer population are APOE4 gene variant +ve: they tend to present earlier and progress more rapidly than those who are APOE4 -ve [3].
Alzheimer's disease in patients who are positive for E4 allele of apoliproprotein E gene
Oral